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Abstract
Introduction: The normalization of cellular glucose assimilation is the basic aim of metabolic therapy in type 2 diabetes mel-
litus (T2DM). It requires parallel changes in the process of cellular glucose transport (CGT). Therefore the level of CGT
could be regarded as a therapeutic target for oral hypoglycemic drugs in T2DM. To explore this hypothesis, CGT levels
before and after sulfonylurea therapy were investigated. Peripheral blood lymphocytes were used as a cell model for testing
CGT. 
Materials and Methods: CGT was assessed by experimental in vitro tests allowing timed comparative observation of the
transport process during the incubation of lymphocytes with 2-[3H(G)] glucose under basal conditions and after the addition
of sulfonylurea or sulfonylurea plus insulin. The incubation tests were performed at baseline in 28 persons with newly diag-
nosed, therapy-naive T2DM and in 20 control subjects. In the diabetic patients the tests for CGT were repeated after 3
months of sulfonylurea therapy. The level of glucotransporter 4 (GLUT4) expression was also assessed by flow cytometry
before and after the therapy.
Results: Before treatment, CGT was significantly lower in the subjects with T2DM. The cells responded to the addition of
sulfonylurea by a moderate increase in CGT. This response was augmented by the addition of insulin to sulfonylurea in the
culture medium.
Conclusions: The three-month therapy with sulfonylurea resulted in a significant increase in CGT in all types of culture tests.
This sulfonylurea-related improvement in CGT was associated with a near normalization of GLUT4 expression in the cells.
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INTRODUCTION
Glucose transport defects in type 2 diabetes mellitus
(T2DM) lead to impairment of the rate of glucose uti-
lization by peripheral tissues. The first step of this com-
plex process is cellular glucose transport (CGT), the
properties of which in peripheral blood lymphocytes of
diabetic patients are not known and information on glu-
cose transporters in these cells is scarce and inconsis-
tent.
As the lipid bilayer membrane of the majority of
cells in the human body is impermeable to monosaccha-
rides, glucose needs a biological transport system con-
sisting of specialized transport proteins, the glucotrans-
porters (GLUTs) (Kahn 1996; Shepherd and Kahn
1999). These proteins provide the physiological balance
between glucose supply in cells and its further metabo-
lism (Czech and Corvera 1999; Shulman 2000). CGT is
a multistage process. Its individual stages are coordinat-
ed by specialized regulatory systems. Under physiologi-
cal conditions the sensitive and quantitative coordina-
tion between the activity of the molecular CGT system
and intracellular glucose metabolism is related to
glycemia. Insulin is among the most important regula-
tors of this relationship (Matthaei et al. 2000). In dia-
betes mellitus, however, this physiological regulation
becomes impaired. Glucose utilization by cells is dimin-
ished despite hyperglycemia. The primary reason
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behind this impairment is insulin deficiency or
a decrease in the peripheral cells’ sensitivity to insulin,
which could involve also the CGT system; in this way,
a special form of insulin resistance may arise. The diag-
nosis and correction of such pathophysiological distur-
bances in CGT should therefore be an aim of therapy. It
follows that CGT may be approached as an important
target for therapeutic drug activity. This refers especial-
ly to insulin therapy and also to use of the oral betacy-
totropic sulfonylureas. This hypothesis can be supported
by many observations which suggest that the activity of
oral betacytotropic drugs is pleiotropic and not limited
solely to the stimulation of beta cells. They produce
many other therapeutically positive effects, among them
a decrease in insulin resistance (Almer 1984; Fava et al.
2002; Gram et al. 1988; Itoh et al. 2003; Jennings et al.
1992; O’Brien et al. 2000). This may also involve the
activity of the CGT system. 
Therefore the clinically important questions arise as to: 
1) whether hypoglycemic betacytotropic sulfony-
lurea derivatives influence the CGT system in a clinical-
ly significant and therapeutically important way; 
2) whether these drugs exert their influence solely by
stimulating insulin secretion or do they diminish hyper-
glycemia also in another way, i.e. by directly influencing
CGT? To answer these pathophisiologically and clini-
cally important questions, special experiments were
designed and performed. 
The investigations included: 
• a comparative assessment of CGT in healthy vol-
unteers and in type 2 diabetes patients who had not
been treated previously in any way;
• investigation of the influence of T2DM treatment
with a sulfonylurea compound on CGT;
• study of changes in the expression of GLUT4, the
glucotransporter playing the most important role in
CGT, that could occur as an effect of treatment with sul-
fonylureas. 
As the cell model for in vitro testing, peripheral
blood lymphocytes of patients with diabetes mellitus
type 2 and healthy subjects were used. 
Study aims
The study aimed specifically at: 
I. determining CGT activity in cells using the model
of peripheral blood lymphocytes. These experiments
were done using originally designed incubation tests
assessing CGT in vitro:
1. in a control group of healthy volunteers:
• under basic conditions: lymphocyte incubation
without additives
• under stimulated conditions:
a) lymphocyte incubation with a sulfonylurea com-
pound; for this purpose, gliclazide was used
b) lymphocyte incubation with addition of sulfony-
lurea and insulin
2. In a study group of patients with newly diagnosed
T2DM not previously treated pharmacologically and
with the same set of cell incubation tests as for the
healthy volunteers: 
a) before and 
b) after 12 weeks of sulfonylurea therapy.
II. In addition, a the comparative flow-cytometric
assessment of GLUT4 expression in the model cells, i.e.
the lymphocytes of healthy subjects and T2DM patients
as described above before and after 12 weeks of sul-
fonylurea therapy.
It was expected that the comparison of the CGT
measurements according to this plan would allow
assessing whether CGT is altered in T2DM under the
influence of therapy with betacytotropic sulfonylureas.
MATERIALS AND METHODS
Diabetes mellitus type 2 and control groups
A group of 28 patients with diabetes mellitus type 2
who were not previously treated pharmacologically was
qualified for the study. The clinical diagnosis of type 2
diabetes was made according to World Health
Organization (WHO) criteria (Pulido et al. 1996).
Qualification of the study population was accepted by
the University Bioethics Council. The subjects chosen
had no pathological disorders other than diabetes melli-
tus type 2. The control group consisted of 20 healthy vol-
unteers with no family history of diabetes. Qualification
was based on a complete medical examination according
to the full protocol of the Warsaw Medical University
clinical standard. 
An 8-point daily glucose profile was taken and
HbA1c determinations were performed in the T2DM
patient group. In the control group an oral glucose tol-
erance test (75.0 g) was performed according to WHO.
The results of the initial clinical examination of both
groups are presented in Table 1.
CGT assessment in peripheral blood lymphocytes in vitro
Lymphocyte suspension samples were taken from
the 20 healthy control subjects and the 28 T2DM
patients, previously untreated for hyperglycemia, before
and after 3 month of sulfonylurea therapy and tested
according to the study plan.
The influence of sulfonylurea treatment on CGT
was studied in three independent series of lymphocyte
incubation tests, i.e. with neither sulfonylurea nor
insulin added, with sulfonylurea added, and with both
sulfonylurea and insulin added. The CGT level was
measured at 15, 30, and 60 min of incubation. In all
cases and samples, the viability of lymphocytes was test-
ed with the trypan blue method.
GLUT4 expression
GLUT4 expression was measured in the lymphocytes
of the same subjects in whom CGT was determined,
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which included 10 healthy control subjects, and 10
T2DM patients before and after sulfonylurea therapy.
Measurement of deoxy-D-glucose uptake by lymphocytes 
The incubation tests were performed according to
previously described methods (Curto et al. 1997; Kaliman
et al. 1995; Szablewski et al. 2000) adapted to our labora-
tory. To 290 µl of a suspension containing 300,000 lym-
phocytes, 1.5 µl of deoxy-D-glucose-2-[3H(G)] (185–370
GBq (7,70000 Cii/mmol) (NEN Life Science Products,
Inc.) and 7.5 µl of phosphate-buffered saline solution
(PBS) were added. Deoxy-D-glucose-2-[3H(G)] uptake
was measured after 15, 30, and 60 min of incubation, after
which the transport was stopped by addition of 2 vol of
ice-cold, 50 mM glucose in PBS. Then the lymphocytes
were washed three times in the same solution and the
cells were lysed with 0.1 mM NaOH/0.1% SDS (sodium
dodecylsulfate). The following day, after cell lyses (within
24 h), radioactivity was determined by a scintillation
counter (Wallac 1450 MicroBeta Trilux). Each procedure
was performed in triplicate.
GLUT4 expression measurements with flow cytometry
Mononuclear cells were isolated from the blood sam-
ples on Gradisol L (fluid density: of 1.077 g/l; “AQUA-
-MEDICA”) and washed twice in 0.9% NaCl. To mark
the population of cells that presents GLUT4 protein
expression, anti-GLUT4 monoclonal antibody was used
together with one-color indirect immunofluorescence.
For every single staining process, a sample of 106
mononuclear cells was taken. The cells were incubated
for 30 min with 2 µl of anti-GLUT4 antibody in an ice
bath of 4°C and then washed with PBS plus 0.01%
NaN3. The cells were then incubated for 20 min (ice
bath, 4°C) with 10 µl of secondary nonspecific antibody
binding to the immunoglobulin fragment F(ab’)2 and
conjugated with the fluorochrome fluorescein isothio-
cyanate (FITC). Later the MNCs were washed again
with PBS plus 0.01% NaN3 and suspended in 500 µl of
FACS Flow (Becton-Dickinson, USA).
For data acquisition and analysis, a FACSCalibur
flow cytometer (Becton-Dickinson, USA) with
CellQuest software (Becton-Dickinson, USA) was used.
The results are given as the percentage of cells present-
ing GLUT4 expression (Pi¹tkiewicz et al. 2007).
Viability test
The trypan blue test showed that the experimental
methods used did not influence lymphocyte viability.
Individual dead cells were observed in the samples both
before and after the experiments. The amount of dead
cells was the same in samples from the control subjects
and from the T2DM patients. The type of hypoglycemic
treatment administered also did not influence lympho-
cyte viability.
Statistical analysis
Comparison of the clinical and demographic para-
meters of the groups was performed using the Mann-
Whitney or chi-squared tests as appropriate. Changes in
the values of diabetes control parameters (HbA1c, FPG,
FSI, HOMA-IR) between the week 0 (W0) and week 12
(W12) visits were investigated with the Wilcoxon test.
Variations in glucose uptake in the peripheral blood
Table 1. Comparative clinical characteristic of the two study population groups: diabetes mellitus type 2
and control group
Parameter Diabetes mellitus type 2 group Control group p
(before treatment) n=20
n=28
mean (SD) mean (SD)
Age, years 58.0 (70) 48.6 (11.4) 0.003
Sex, M/F 20/8 8/12
BMI, kg/m2 28.49 (2.21) 27.68 (2.44) 0.235
Blood pressure, mmHg:
systolic 135 (14.8) 127.3 (13.3) 0.060
diastolic 79 (8.0) 77.0 (9.2) 0.365
Resting heart rate (min) 80.0 (7.4) 80.4 (8.7) 0.865
FPG, mmol/l 8.05 (1.03) 5.13 (0.66) <0.001
FSI, µU/ml 12.15 (7.88) 7.92 (3.76) 0.019
HOMA-IR 4.368 (2.806) 1.844 (1.008) <0.001
HbA1c (%) 6.83 (0.86) –
Creatinine, serum, mg/dl 1.020 (0.310) 0.944 (0.177) 0.291
AspAT, IU/dl 25.5 (8.1) 20.6 (5.9) 0.024
AlAT, IU/dl 26.9 (13.6) 24.0 (10.4) 0.426
FPG – fasting plasma glucose, FSI – fasting serum insulin, HOMA-IR – homeostatic model assessment-
-insulin resistance, AspAT – aspartate transaminase, serum, AlAT – alanine transaminase, serum.
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lymphocytes were analyzed with the Mann-Whitney test
(Armitage 1971).
RESULTS
CGT assessment in peripheral blood lymphocytes, 
control group and diabetes mellitus group before therapy
with sulfonylurea (W0)
The incubation tests with the lymphocytes of the
control subjects showed an active CGT. Its intensity
clearly increased with the duration of incubation. The
addition of sulfonylurea to the culture enhanced CGT
by a statistically significant amount for the all investigat-
ed incubation times. The addition of sulfonylurea and
insulin together intensified CGT at 15 and 30 min. This
did not occur at the incubation time of 60 min (Table 2). 
The incubation tests with the lymphocytes of the dia-
betic patients showed that when sulfonylurea was not
added to the incubation environment, the CGT values
were lower than those in the healthy controls. The influ-
ences of sulfonylurea and sulfonylurea plus insulin
added to the culture were distinctly weaker than in the
healthy controls (Table 2).
The influence of sulfonylurea on CTG in peripheral
blood lymphocytes after sulfonylurea therapy (W12)
Diabetes mellitus metabolic compensation parameters
measured before the start of treatment and after 12 weeks
of treatment with sulfonylureas significantly improved.
Fasting plasma glucose concentration decreased signifi-
cantly (on average by 1.77 mmol/l, p<0.001). This was
associated with a decrease in HbA1c level (on average by
0.69%, p<0.001). Fasting plasma insulin concentration
increased at the same time, on average by 2.65 µU/ml
(p<0.022). The HOMA-IR index did not change.
CGT intensity was significantly and consistently
higher 12 weeks after treatment with sulfonylurea than
before, as shown in all the incubation tests. Increased
glucose uptake was clearly observed. The CGT level
after therapy was similar to that measured in the control
group (Table 2).
GLUT4 expression
The results of GLUT4 expression in the peripheral
blood lymphocytes of the control subjects and T2DM
patients before and after 12 weeks of sulfonylurea treat-
ment are presented in Table 3. As the results show,
GLUT4 expression was observed in 0.6% of the lympho-
cytes of the control subjects. In T2DM patients this value
was much higher (15.5%) before treatment. Twelve weeks
after the begin of sulfonylurea treatment, the level of
GLUT4 expression diminished to a mean value of 2.7%.
DISCUSSION
So far, the clinical study of CGT concerns only
selected areas. It has, however, provided valuable infor-
Table 2. CGT intensity measured in incubation tests in vitro for peripheral blood lymphocytes taken from 20 control subjects and
from type 2 diabetic patients (T2DP) at baseline and after the completion of 12 weeks gliclazide treatment, expressed in
pg/300,000 lymphocytes
Sample Model Incubation CGT intensity (pg/300,000 lymphocytes)
time (min)
mean SD mean SD mean SD
1 Lymphocytes, 15` 123.1 25.7 106.4 25.3 162.4 34.6
no drugs added 30` 228.7 58.8 179.4 32.3 308.1 57.5
60` 442.8 137.8 263.1 47.8 543.6 62.1
2 Lymphocytes, 15` 203.6 49.1 113.5 25.8 210.3 36.7
gliclazide added 30` 417.1 107.1 199.0 36.3 412.0 97.3
60` 664.1 186.8 316.2 57.8 727.2 147.5
3 Lymphocytes, gliclazide 15` 308.8 87.2 186.4 28.4 349.3 54.5
and insulin added 30` 647.7 181.5 293.3 56.7 689.6 145.2
60` 666.7 186.4 306.0 57.1 709.7 150.0
Control subjects T2DP at baseline T2DP after 12 weeks 
p p of gliclazide treatment
p
sample 2 vs. 1 15`<0.001 15`<0.118 15`<0.001
30`<0.001 30`<0.001 30`<0.001
60`<0.001 60`<0.001 60`<0.001
sample 3 vs. 2 15`<0.001 15`<0.001 15`<0.001
30`<0.001 30`<0.001 30`<0.001
60`<0.469 60`<0.001 60`<0001
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mation regarding the activity and regulation of CGT
and glucotransporter expression under various metabol-
ic conditions, both physiological and pathological
(Galuska et al. 1994; Pi¹tkiewicz et al. 2007; Pulido et al.
1997; Szablewski et al. 2000; Tsiani et al. 1995). In the
majority of studies, myocytes or adipocytes were used as
the experimental model, while other cell models were
practically ignored. The pharmacological aspects of
CGT were also rarely addressed. 
Peripheral blood cells, among them lymphocytes,
constitute a model which has been shown to be very use-
ful in pharmacological research (Chakrabarti et al. 1994;
Daneman et al. 1992; Pulido et al. 1997; Pulido 2000;
Vestergaard et al. 1995). They represent the overall
CGT process. The investigation of glucose transport in
peripheral blood cells is also interesting because it
involves issues not yet fully ascertained and which may
be clinically very significant due to lymphocytes’ role
and function (Estrada et al. 1994).
It is widely assumed that the increased susceptibility
to infections observed in diabetes mellitus may be relat-
ed to lymphocytic function abnormalities resulting from
their pathological decrease of glucose metabolism
(Pi¹tkiewicz et al. 2007). This in turn may be due to
impaired CGT (Estrada et al. 1994; Korgun et al. 2002)
and abnormalities in the expression of glucotrans-
porters.
Several studies have so far revealed that GLUTl,
GLUT3, GLUT4, and GLUT9 are present in granulo-
cytes and monocytes (Chakrabarti et al. 1994; Daneman
et al. 1992; Dimitriadis et al. 2005; Joshi et al. 1999).
GLUTl, GLUT3, and GLUT 9 expression has been
shown in lymphocytes (Dimitriadis et al. 2005; Joshi et
al. 1999; Otton et al. 2002). Surprisingly, in study results
available to date, no GLUT4 expression in lymphocytes
of healthy people has been observed (Longo and Elsas
1998; Phay et al. 2000). The expression of GLUT1 gene
in lymphocytes from rat spleen increased under the
influence of physical exercise (Phay et al. 2000). On the
other hand, it has been shown that sustained hypo-
glycemia affects GLUT gene expression in human blood
leukocytes, especially in granulocytes and monocytes. In
granulocytes, the level of GLUT4 increases in this situ-
ation by 73% compared with control samples, whereas
a simultaneous reduction in GLUT1 and GLUT3 is
observed. No such effect has been observed in the lym-
phocyte population (Chakrabarti et al. 1994).
There are several examples of pharmacological
research into CGT in experimental animals. Tsiani et al.
investigated the influence of sulfonylurea on CGT
intensity and on glucose transporter distribution in rat
muscle tissue cells in vitro. They demonstrated that sul-
fonylurea causes a significant increase in CGT, inde-
pendently of insulin. This correlated with an increase in
GLUT1 expression in the plasma membrane of the test-
ed cells (Pi¹tkiewicz et al. 2007). 
Interesting information concerning the influence of
sulfonylurea on CGT in rat muscles was also presented
by Pulido et al. (Galuska et al. 1994; Tsiani et al. 1995).
Sulfonylurea increased CGT and enhanced GLUT4
translocation to the cell membrane. This direct effect
was stimulated by insulin. A sulfonylurea compound
administered to rats with streptozocine-induced dia-
betes mellitus normalized both GLUT4 expression and
CGT in skeletal muscle tissue (Galuska et al. 1994).
The presented results of the CGT clinical therapeu-
tic investigation with a lymphocyte model using incuba-
tion tests demonstrated abnormalities in CGT function
in both untreated and sulfonylurea-treated type 2 dia-
betic patients. The experiments revealed that sulfony-
lurea therapy significantly affects CGT in a clinically sig-
nificant way. 
Comparison of the CGT values measured in the incu-
bation tests at time periods of 15, 30, and 60 min in healthy
subjects and T2DM patients both untreated and subjected
to 12 weeks of sulfonylurea treatment provides important
information on this issue. It was determined that in
untreated T2DM patients the CGT values were always
significantly lower than those of the healthy controls. The
differences were statistically significant. In untreated
T2DM patients, two phenomena coexisted: hyper-
glycemia and a significant decrease in CGT. This compar-
ison validates the hypothesis that the CGT increase under
the influence of sulfonylurea therapy may contribute to
the decrease in hyperglycemia level in T2DM. This was
confirmed by the observation of the effect of sulfonylurea
therapy on CGT in the same patients before and after
therapy. After 12 weeks of treatment with sulfonylurea,
the previously decreased CGT level increased to a similar
efficacy as that observed in the healthy controls. This ther-
apeutic effect correlated with significant decreases in fast-
ing glucose concentration and HbA1c percentage. It may
then be implied that sulfonylurea treatment increases
CGT, simultaneously influencing these T2DM control
Table 3. The percentage of peripheral blood lymphocytes presenting GLUT4 expression in control group and in type 2 diabetic
patients before and after 12 weeks of gliclazide treatment
Percentage of lymphocytes with GLUT4 expression
Control subjects T2DM patients
mean SD before gliclazide treatment (W0) after 12 weeks of gliclazide treatment (W12)
mean SD mean SD
0.6 0.3 15.5 9.8 2.7 1.6
p(W0 vs W12)=0.002
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parameters. It therefore constitutes a measure and a tar-
get of therapy.
Such a notion may be further substantiated by the
observed changes in GLUT4 expression in lymphocytes
induced at the same time by sulfonylurea treatment.
They accompanied the CGT increase.
In the T2DM patients, two effects were noted simul-
taneously: increased CGT and decreased GLUT4
expression, both close to the values observed in healthy
people. The decrease in GLUT4 expression was from
a mean value of 15.5% to a mean value of 2.7% of cells
(p<0.001) as measured with flow cytometry. This is also
definitely a positive therapeutic effect. Our observations
suggest that sulfonylurea therapy also works at the level
of peripheral cells, directly effecting the CGT system. 
To summarize, the use of sulfonylurea drugs in
T2DM treatment simultaneously exerted a positive
pleiotropic therapeutic influence on both CGT intensity
and GLUT4 expression.
In conclusion it could be stated, that: 1) the incuba-
tion tests showed that lymphocytes constitute a useful
model for CGT investigations. In healthy subjects, the
increase in CGT intensity is proportional to incubation
time. CGT values in lymphocytes from healthy controls
and tested in vitro also increase under the influence of
sulfonylurea as well as under the influence of sulfony-
lurea and insulin together; 2) in pharmacologically
untreated T2DM, CGT is diminished compared with
healthy controls. This difference is statistically signifi-
cant. The reaction of CGT to the addition of sulfony-
lurea and sulfonylurea together with insulin is also sig-
nificantly reduced; 3) prolonged, 12-week sulfonylurea
treatment causes a statistically significant increase in
CGT in the studied cells; 4) in type 2 diabetic patients
treated with sulfonylurea, the increase in CGT reaches
the level encountered in healthy controls. It coexists
with changes in GLUT4 expression. Under the influ-
ence of sulfonylurea therapy, the elevated GLUT4
expression before treatment decreases to the level
observed in healthy controls. 
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